The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Value Is Expected For The Personalized Cell Therapy Market At The End Of The 2026–2030 Forecast Period?
The personalized cell therapy market has demonstrated exponential growth in its size during recent years. This market is anticipated to expand from $20.83 billion in 2025 to $25.42 billion in 2026, registering a compound annual growth rate (CAGR) of 22.1%. The growth observed in the historic period was largely influenced by the limited availability of autologous cell therapies, a high dependency on conventional treatments, a deficiency in advanced biomanufacturing infrastructure, slow regulatory approvals, and low patient awareness of personalized therapies.
The personalized cell therapy market is anticipated to experience substantial expansion over the coming years. It is projected to reach $56.46 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 22.1%. This projected growth during the forecast period stems from the increasing need for autologous and allogeneic cell therapies, the rising integration of AI-driven treatment optimization, enhanced government and private sector investment in cell therapy research, wider applications across cancer, cardiovascular, and autoimmune conditions, and burgeoning collaborations between biotechnology companies and research institutions. Prominent trends for the forecast period comprise the greater acceptance of genomic-based cell therapy methods, the increasing application of personalized immunotherapy strategies, the expanding incorporation of digital platforms for cell therapy administration, the growing utilization of AI and big data in cell therapy investigations, and increasing capital expenditure in biomanufacturing and scalable cell production.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19137&type=smp
What Major Growth Drivers Are Shaping The Outlook Of The Personalized Cell Therapy Market?
The personalized cell therapy market is poised for growth due to an anticipated rise in neurological disorders. These conditions encompass a range of ailments affecting the brain, spinal cord, and nerves, resulting in symptoms like impaired motor function, cognitive deficits, and sensory disturbances. The increasing occurrence of neurological disorders is linked to an aging population, environmental stressors, and lifestyle changes, which contribute to higher incidences of neurodegenerative diseases. Personalized cell therapy is crucial for neurological disorders as it delivers tailored treatments targeting specific patient requirements, with the potential to restore damaged neural tissue and enhance outcomes in complex, individualized conditions. For instance, in April 2024, an article in Neurology, a US-based publication of the American Academy of Neurology, projected that global cases of brain disorders, also known as neurological disorders, are expected to increase by approximately 22% by the year 2050. Therefore, the growing number of neurological disorders is propelling the expansion of the personalized cell therapy market.
What Segment Types Make Up The Personalized Cell Therapy Market?
The personalized cell therapy market covered in this report is segmented –
1) By Cell Type: Lymphocytes, Mesenchymal Stem Cells (MSCs), Hematopoietic Stem Cells, Other Cell Types
2) By Technique: Cell Engineering And Expansion Techniques, Bone Marrow Transplantation, Autologous Cell Infusion Techniques, Adoptive Cell Transfer Techniques
3) By Application: Cardiovascular Diseases, Neurological Disorders, Inflammatory Diseases, Diabetes, Cancer, Other Applications
4) By End-User: Hospital, Cell Therapy Treatment Centers, Specialty Clinics, Other End-Users
Subsegments:
1) By Lymphocytes: T Cells, Natural Killer (NK) Cells, Regulatory T Cells
2) By Mesenchymal Stem Cells (MSCs): Bone Marrow-Derived MSCs, Adipose Tissue-Derived MSCs, Umbilical Cord-Derived MSCs
3) By Hematopoietic Stem Cells: Autologous Hematopoietic Stem Cells, Allogeneic Hematopoietic Stem Cells
4) By Other Cell Types: Dendritic Cells, Fibroblasts, Endothelial Cells
What Industry Trends Are Redefining The Personalized Cell Therapy Market?
Key companies within the personalized cell therapy market are concentrating on groundbreaking therapies like closed-system sterility, which facilitates the uncontaminated processing of patient-derived cells from their initial collection to their final preparation. Closed-system sterility describes a technique for processing cells that prevents any exposure to the external environment, thus ensuring their sterility throughout the entire manufacturing or handling procedure. For example, in March 2025, Limula SA, a Switzerland-based firm dedicated to advanced cell therapy solutions, introduced LimONE, an automated cell therapy manufacturing platform. This launch signified a notable progression aimed at optimizing the production of personalized treatments such as CAR-T and hematopoietic stem cell therapies. Moreover, this platform offers a closed-system sterile workflow and enables more consistent patient-specific cell therapy production.
Who Are The Key Players Driving Competition In The Personalized Cell Therapy Market?
Major companies operating in the personalized cell therapy market are Bristol-Myers Squibb Company, GlaxoSmithKline plc, Gilead Sciences Inc., Poseida Therapeutics Inc., Sangamo Therapeutics Inc., Nkarta Therapeutics Inc., Intellia Therapeutics Inc., Tessa Therapeutics Pte Ltd, Atara Biotherapeutics Inc., Adaptimmune Therapeutics plc, Precision BioSciences Inc., Editas Medicine Inc., Cellectis S.A., Gracell Biotechnologies Inc., Mesoblast Limited, Fate Therapeutics Inc., Athersys Inc., Bellicum Pharmaceuticals Inc., Celyad Oncology SA, Century Therapeutics Inc., Gamida Cell Ltd., CRISPR Therapeutics AG, Allogene Therapeutics Inc., Bluebird bio Inc., Autolus Therapeutics plc
Read the full personalized cell therapy market report here:
https://www.thebusinessresearchcompany.com/report/personalized-cell-therapy-global-market-report
Which Regions Are Projected To Dominate The Personalized Cell Therapy Market In The Coming Years?
North America was the largest region in the personalized cell therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized cell therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Personalized Cell Therapy Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=19137&type=smp
Browse Through More Reports Similar to the Global Personalized Cell Therapy Market 2026, By The Business Research Company
Cancer Supportive Care Drugs Global Market Report
https://www.thebusinessresearchcompany.com/report/cancer-supportive-care-drugs-global-market-report
Cancer Supportive Care Products Global Market Report
Cancer Profiling Global Market Report
https://www.thebusinessresearchcompany.com/report/cancer-profiling-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
